Skip to main content
Top
Published in: Diabetologia 10/2011

01-10-2011 | Article

Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes

Authors: M. C. Thomas, J. Söderlund, M. Lehto, V.-P. Mäkinen, J. L. Moran, M. E. Cooper, C. Forsblom, P.-H. Groop, on behalf of the FinnDiane Study Group

Published in: Diabetologia | Issue 10/2011

Login to get access

Abstract

Aims/hypothesis

Activation of the receptor for AGE (RAGE) is implicated in the development and progression of vascular complications of diabetes. In this study, we explore factors and mortality outcomes associated with soluble RAGE (sRAGE) in a multicentre nationwide cohort of Finnish adults with type 1 diabetes.

Methods

Baseline sRAGE concentrations were estimated in 3,100 adults with type 1 diabetes. Clinical and biological variables independently associated with sRAGE were identified using multivariate regression analysis. Independent predictors of mortality were determined using Cox and Fine–Gray proportional-hazards models.

Results

The main independent determinants of sRAGE concentrations were estimated glomerular filtration rate, albuminuria, body mass index, age, duration of diabetes, HbA1c and insulin dose (all p < 0.05). During a median of 9.1 years of follow-up there were 202 deaths (7.4 per 1,000 patient years). sRAGE was independently associated with all-cause (Cox model: HR 1.03) and cardiovascular mortality (Fine–Gray competing risks model: HR 1.06) such that patients with the highest sRAGE concentrations had the greatest risk of mortality, after adjusting for age, sex, macrovascular disease, HDL-cholesterol, HbA1c, triacylglycerol, high-sensitivity C-reactive protein (hsCRP) and the presence and severity of chronic kidney disease. Although polymorphisms in the gene coding for RAGE were significantly associated with sRAGE concentrations, none were associated with mortality outcomes.

Conclusions/interpretation

Increased concentrations of sRAGE are associated with increased all-cause and cardiovascular mortality in type 1 diabetes, potentially reflecting the activation and production of RAGE in the context of accelerated vascular disease. These novel findings highlight the importance of the RAGE activation in the prevention and management of diabetic complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597–605PubMedCrossRef Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597–605PubMedCrossRef
2.
go back to reference Soro-Paavonen A, Watson AM, Li J et al (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461–2469PubMedCrossRef Soro-Paavonen A, Watson AM, Li J et al (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461–2469PubMedCrossRef
3.
go back to reference Bucciarelli LG, Wendt T, Qu W et al (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827–2835PubMedCrossRef Bucciarelli LG, Wendt T, Qu W et al (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827–2835PubMedCrossRef
4.
go back to reference Wendt TM, Tanji N, Guo J et al (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123–1137PubMedCrossRef Wendt TM, Tanji N, Guo J et al (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123–1137PubMedCrossRef
5.
go back to reference Zhang L, Bukulin M, Kojro E et al (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 283:35507–35516PubMedCrossRef Zhang L, Bukulin M, Kojro E et al (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 283:35507–35516PubMedCrossRef
6.
go back to reference Yonekura H, Yamamoto Y, Sakurai S et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097–1109PubMedCrossRef Yonekura H, Yamamoto Y, Sakurai S et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097–1109PubMedCrossRef
7.
go back to reference Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL (2005) Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 51:1749–1750PubMedCrossRef Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL (2005) Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 51:1749–1750PubMedCrossRef
8.
go back to reference Koyama H, Shoji T, Yokoyama H et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25:2587–2593PubMedCrossRef Koyama H, Shoji T, Yokoyama H et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25:2587–2593PubMedCrossRef
9.
go back to reference Forbes JM, Thorpe SR, Thallas-Bonke V et al (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16:2363–2372PubMedCrossRef Forbes JM, Thorpe SR, Thallas-Bonke V et al (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16:2363–2372PubMedCrossRef
10.
go back to reference Gohda T, Tanimoto M, Moon JY et al (2008) Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 81:196–201PubMedCrossRef Gohda T, Tanimoto M, Moon JY et al (2008) Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract 81:196–201PubMedCrossRef
11.
go back to reference Semba RDFL, Fink JC, Sun K et al (2009) Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53:51–58PubMedCrossRef Semba RDFL, Fink JC, Sun K et al (2009) Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53:51–58PubMedCrossRef
12.
go back to reference Jang Y, Kim JY, Kang SM et al (2007) Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56:199–205PubMedCrossRef Jang Y, Kim JY, Kang SM et al (2007) Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56:199–205PubMedCrossRef
13.
go back to reference Kalousova M, Jachymova M, Mestek O et al (2007) Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020–2026PubMedCrossRef Kalousova M, Jachymova M, Mestek O et al (2007) Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020–2026PubMedCrossRef
14.
go back to reference Catalano M, Cortelazzo A, Santi R et al (2008) The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (receptor for advanced glycation endproducts) and the presence of peripheral arterial disease. Clin Biochem 41:981–985PubMedCrossRef Catalano M, Cortelazzo A, Santi R et al (2008) The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (receptor for advanced glycation endproducts) and the presence of peripheral arterial disease. Clin Biochem 41:981–985PubMedCrossRef
15.
go back to reference Kankova K, Kalousova M, Hertlova M, Krusova D, Olsovsky J, Zima T (2008) Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch Physiol Biochem 114:111–119PubMedCrossRef Kankova K, Kalousova M, Hertlova M, Krusova D, Olsovsky J, Zima T (2008) Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch Physiol Biochem 114:111–119PubMedCrossRef
16.
go back to reference Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037PubMedCrossRef Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037PubMedCrossRef
17.
go back to reference Lindsey JB, de Lemos JA, Cipollone F et al (2009) Association between circulating soluble receptor for advanced glycation end products (sRAGE) and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 32:1218–1220PubMedCrossRef Lindsey JB, de Lemos JA, Cipollone F et al (2009) Association between circulating soluble receptor for advanced glycation end products (sRAGE) and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 32:1218–1220PubMedCrossRef
18.
go back to reference Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46:1402–1407PubMedCrossRef Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46:1402–1407PubMedCrossRef
19.
go back to reference Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651–1658PubMedCrossRef Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651–1658PubMedCrossRef
20.
go back to reference Makinen VP, Forsblom C, Thorn LM et al (2008) Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 57:2480–2487PubMedCrossRef Makinen VP, Forsblom C, Thorn LM et al (2008) Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 57:2480–2487PubMedCrossRef
21.
go back to reference Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMed Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMed
22.
go back to reference Force ICGT (2005) Global guideline for type 2 diabetes. International Diabetes Federation, Brussels Force ICGT (2005) Global guideline for type 2 diabetes. International Diabetes Federation, Brussels
23.
go back to reference Vandenplas S, Wiid I, Grobler-Rabie A et al (1984) Blot hybridisation analysis of genomic DNA. J Med Genet 21:164–172PubMedCrossRef Vandenplas S, Wiid I, Grobler-Rabie A et al (1984) Blot hybridisation analysis of genomic DNA. J Med Genet 21:164–172PubMedCrossRef
24.
go back to reference Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229PubMedCrossRef Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229PubMedCrossRef
25.
go back to reference Fine J, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef Fine J, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef
26.
go back to reference Pintilie M (2006) Competing risks: a practical perspective. Wiley, Chichester Pintilie M (2006) Competing risks: a practical perspective. Wiley, Chichester
27.
go back to reference Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ (2007) Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg 83:1586–1592PubMedCrossRef Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ (2007) Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg 83:1586–1592PubMedCrossRef
28.
go back to reference Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME (2004) The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 92:S105–S107PubMedCrossRef Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME (2004) The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 92:S105–S107PubMedCrossRef
29.
go back to reference Royston P (2006) Explained variation for survival models. Stata J 6:83–96 Royston P (2006) Explained variation for survival models. Stata J 6:83–96
30.
go back to reference Royston P (2000) A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med 19:1831–1847PubMedCrossRef Royston P (2000) A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med 19:1831–1847PubMedCrossRef
31.
go back to reference Barr EL, Zimmet PZ, Welborn TA et al (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116:151–157PubMedCrossRef Barr EL, Zimmet PZ, Welborn TA et al (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116:151–157PubMedCrossRef
32.
go back to reference Smith GD, Timpson N, Ebrahim S (2008) Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med 40:524–541PubMedCrossRef Smith GD, Timpson N, Ebrahim S (2008) Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med 40:524–541PubMedCrossRef
33.
go back to reference Elliott P, Chambers JC, Zhang W et al (2009) Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302:37–48PubMedCrossRef Elliott P, Chambers JC, Zhang W et al (2009) Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302:37–48PubMedCrossRef
34.
go back to reference Hou FF, Ren H, Owen WF Jr et al (2004) Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15:1889–1896PubMedCrossRef Hou FF, Ren H, Owen WF Jr et al (2004) Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15:1889–1896PubMedCrossRef
35.
go back to reference Nin JW, Ferreira I, Schalkwijk CG et al (2009) Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 52:705–714PubMedCrossRef Nin JW, Ferreira I, Schalkwijk CG et al (2009) Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 52:705–714PubMedCrossRef
36.
go back to reference Nin JW, Jorsal A, Ferreira I et al (2010) Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 59:2027–2032PubMedCrossRef Nin JW, Jorsal A, Ferreira I et al (2010) Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 59:2027–2032PubMedCrossRef
37.
go back to reference Koyama H, Shoji T, Fukumoto S et al (2007) Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27:147–153PubMedCrossRef Koyama H, Shoji T, Fukumoto S et al (2007) Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27:147–153PubMedCrossRef
38.
go back to reference Ramasamy R, Yan SF, Schmidt AM (2009) RAGE: therapeutic target and biomarker of the inflammatory response—the evidence mounts. J Leukoc Biol 86:505–512PubMedCrossRef Ramasamy R, Yan SF, Schmidt AM (2009) RAGE: therapeutic target and biomarker of the inflammatory response—the evidence mounts. J Leukoc Biol 86:505–512PubMedCrossRef
39.
go back to reference Nakamura K, Yamagishi S, Adachi H et al (2007) Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13:185–189PubMedCrossRef Nakamura K, Yamagishi S, Adachi H et al (2007) Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13:185–189PubMedCrossRef
40.
go back to reference Nakamura K, Yamagishi S, Adachi H et al (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76:52–56PubMedCrossRef Nakamura K, Yamagishi S, Adachi H et al (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76:52–56PubMedCrossRef
41.
go back to reference Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL (2008) Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 34:392–395PubMedCrossRef Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL (2008) Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 34:392–395PubMedCrossRef
42.
go back to reference Comper WD, Haraldsson B, Deen WM (2008) Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 19:427–432PubMedCrossRef Comper WD, Haraldsson B, Deen WM (2008) Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 19:427–432PubMedCrossRef
43.
go back to reference Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590–596PubMedCrossRef Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590–596PubMedCrossRef
44.
go back to reference Santilli F, Bucciarelli L, Noto D et al (2007) Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43:1255–1262PubMedCrossRef Santilli F, Bucciarelli L, Noto D et al (2007) Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43:1255–1262PubMedCrossRef
45.
go back to reference Geroldi D, Falcone C, Emanuele E et al (2005) Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23:1725–1729PubMedCrossRef Geroldi D, Falcone C, Emanuele E et al (2005) Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23:1725–1729PubMedCrossRef
46.
go back to reference Jager KJ, Stel VS, Wanner C, Zoccali C, Dekker FW (2007) The valuable contribution of observational studies to nephrology. Kidney Int 72:671–675PubMedCrossRef Jager KJ, Stel VS, Wanner C, Zoccali C, Dekker FW (2007) The valuable contribution of observational studies to nephrology. Kidney Int 72:671–675PubMedCrossRef
Metadata
Title
Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes
Authors
M. C. Thomas
J. Söderlund
M. Lehto
V.-P. Mäkinen
J. L. Moran
M. E. Cooper
C. Forsblom
P.-H. Groop
on behalf of the FinnDiane Study Group
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2186-5

Other articles of this Issue 10/2011

Diabetologia 10/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.